KR850007559A - 조절 펩타이드의 삽입식 제형 - Google Patents

조절 펩타이드의 삽입식 제형 Download PDF

Info

Publication number
KR850007559A
KR850007559A KR1019850002402A KR850002402A KR850007559A KR 850007559 A KR850007559 A KR 850007559A KR 1019850002402 A KR1019850002402 A KR 1019850002402A KR 850002402 A KR850002402 A KR 850002402A KR 850007559 A KR850007559 A KR 850007559A
Authority
KR
South Korea
Prior art keywords
active compound
formulation
zein
mixture
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019850002402A
Other languages
English (en)
Korean (ko)
Inventor
쿠르트 잔도우 위르겐 (외 1)
Original Assignee
하인리히 벡커 베른하르트 벡크
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커 베른하르트 벡크, 훽스트 아크티엔게젤샤프트 filed Critical 하인리히 벡커 베른하르트 벡크
Publication of KR850007559A publication Critical patent/KR850007559A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019850002402A 1984-04-11 1985-04-10 조절 펩타이드의 삽입식 제형 Withdrawn KR850007559A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3413608.8 1984-04-11
DE19843413608 DE3413608A1 (de) 1984-04-11 1984-04-11 Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
KR850007559A true KR850007559A (ko) 1985-12-07

Family

ID=6233259

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850002402A Withdrawn KR850007559A (ko) 1984-04-11 1985-04-10 조절 펩타이드의 삽입식 제형

Country Status (12)

Country Link
EP (1) EP0158277A3 (enExample)
JP (1) JPS60228411A (enExample)
KR (1) KR850007559A (enExample)
AU (1) AU4105985A (enExample)
DE (1) DE3413608A1 (enExample)
DK (1) DK162385A (enExample)
ES (1) ES8607732A1 (enExample)
GR (1) GR850905B (enExample)
HU (1) HUT40760A (enExample)
IL (1) IL74848A0 (enExample)
PT (1) PT80252B (enExample)
ZA (1) ZA852639B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US5137874A (en) * 1985-07-29 1992-08-11 American Cyanamid Co. Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
AU601736B2 (en) * 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
AU2902289A (en) * 1987-12-08 1989-07-05 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CA2170641C (en) 1993-08-30 2011-11-15 James R. Smith Senescent cell-derived inhibitors of dna synthesis
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
US7138511B1 (en) 1997-01-28 2006-11-21 The Regents Of The University Of California Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en) 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6171788B1 (en) 1997-01-28 2001-01-09 The Regents Of The University Of California Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
EP1751115A4 (en) 2004-05-23 2010-10-20 Gerard M Housey THERAMUTEINMODULATOREN
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
EP2163562B1 (en) 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
EP1981560B1 (en) * 2006-01-05 2010-09-08 Med Institute, Inc. Zein coated medical device
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
CA3056116A1 (en) 2007-06-22 2008-12-31 Randolph Watnick Methods and uses thereof of prosaposin
WO2009067431A2 (en) 2007-11-20 2009-05-28 Cook Incorporated Controlled drug delivery using a zein layer modified with levulinic acid
HRP20141194T1 (hr) 2007-12-20 2015-04-24 Xoma (Us) Llc Postupci lijeäśenja gihta
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN101669899B (zh) * 2009-09-29 2011-02-02 河北科技大学 玉米蛋白为主要骨架材料或基质的缓释埋植剂及其用途
EP2513137B1 (en) 2009-12-17 2018-02-28 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
CN101843577A (zh) * 2010-04-08 2010-09-29 安徽中医学院 以玉米醇溶蛋白为骨架材料的包衣植入剂及制备方法
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
ES2664224T3 (es) 2011-08-19 2018-04-18 Children's Medical Center Corporation Proteína de unión a VEGF para el bloqueo de la angiogénesis
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
AU2012358269B2 (en) 2011-12-22 2017-11-02 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
JP6687520B2 (ja) 2013-07-18 2020-04-22 トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー 極めて長い相補性決定領域を有するヒト化抗体
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
EP3057991B8 (en) 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
EP3057994B1 (en) 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP2977758A1 (en) 2014-07-24 2016-01-27 Université De Nice Sophia Antipolis Methods and kits for monitoring membranous nephropathy
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
US20220380487A1 (en) 2019-10-24 2022-12-01 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
EP4514389A1 (en) 2022-04-29 2025-03-05 Purinomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE184774C (enExample) *
US2895880A (en) * 1955-05-13 1959-07-21 Smith Kline French Lab Sustained release pharmaceutical product
GB935672A (en) * 1960-07-19 1963-09-04 Sterling Drug Inc Sustained release tablet
DE2242844A1 (de) * 1972-08-31 1974-04-11 Wolfgang Joachim Guettner Spruehmittel auf zein-basis
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance

Also Published As

Publication number Publication date
PT80252A (de) 1985-05-01
ES8607732A1 (es) 1986-06-01
DE3413608A1 (de) 1985-10-24
EP0158277A3 (de) 1987-04-29
IL74848A0 (en) 1985-07-31
AU4105985A (en) 1985-10-17
JPS60228411A (ja) 1985-11-13
HUT40760A (en) 1987-02-27
PT80252B (de) 1987-02-03
DK162385A (da) 1985-10-12
ZA852639B (en) 1985-11-27
EP0158277A2 (de) 1985-10-16
GR850905B (enExample) 1985-11-25
ES542045A0 (es) 1986-06-01
DK162385D0 (da) 1985-04-10

Similar Documents

Publication Publication Date Title
KR850007559A (ko) 조절 펩타이드의 삽입식 제형
CA2009890A1 (en) Valproic acid
SE8303531D0 (sv) Farmaceutisk komposition
DK74187A (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
AU594992B2 (en) System for the controlled-rate release of active substances
AU558164B2 (en) Lyophilised composition of gelatin and leucine
JPS643193A (en) Cell and tissue reparative agent
KR890007739A (ko) 안정화된 의약물질, 이의 제조방법, 및 안정한 의약제제
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
DE69434626D1 (de) Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
IE800117L (en) Depot body on the basis of silicone rubber for sustained¹drug release
HK59681A (en) Pharmaceutical compositions for use in the suppression of gastric reflux
IE782317L (en) Biologically active peptides
ATE228005T1 (de) Pharmazeutische formulierungen aus corticotropin freisetzenden faktor mit verbesserter stabilitaet in fluessiger form
LV11818A (lv) Jauna farmaceitiska kompozicija stabilas pulverveida zalu formas pagatavosanai
DE69531736D1 (de) Oxytetracyclin enthaltendes arzneimittel mit verzögerter wirksoffabgabe
KR840004347A (ko) 불안정한 약물 또는 음식물 첨가물의 안정화
ATE226428T1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
EP0083835A3 (en) Stabilization of diazo-resin sensitisers
IE801402L (en) Gastric acid neutralizing agents
ES2043351T3 (es) Preparado farmaceutico para el tratamiento de enfermedades hepaticas.
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
KR920018076A (ko) 신규 폴리펩티드
JPS5750914A (en) Betamethasone external pharmaceutical
EP0362731A3 (de) Verfahren zur Herstellung von Arzneimittelwirkstoff-Partikeln mit verbesserten Fliess-, Lager- und Formulierungseigenschaften sowie Arzneimittel, die diese Arzneimittelwirkstoff-Partikeln enthalten

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19850410

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid